Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I trial to evaluate the safety, tolerability and pharmacokinetics of ADX 71441

Trial Profile

Phase I trial to evaluate the safety, tolerability and pharmacokinetics of ADX 71441

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Jan 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ADX 71441 (Primary)
  • Indications Alcoholism; Charcot-Marie-Tooth disease; Smoking withdrawal
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 09 Jan 2017 According to an Addex Therapeutics media release, this trial is scheduled to start in 2017.
    • 11 Apr 2016 According to an Addex Therapeutics media release, ADX71441 received regulatory approval to start phase I and will be investigated in Charcot-Marie-Tooth Type 1A disease (CMT1A), alcohol use disorder and nicotine dependence with support from the US CMT Association, the US National Institute on Alcohol Abuse and Alcoholism, and the US National Institute on Drug Abuse, respectively.
    • 01 May 2013 Addex Therapeutics expected to initiate this trial during the H1 of 2013. The trial was planned to initially focus on evaluating ADX 71441 for the treatment of spasticity in patients with multiple sclerosis (MS). Following positive proof-of-concept data, Addex plans to move to phase IIa testing for Charcot-Marie-Tooth 1A (CMT1A) disease. Addex is developing ADX 71441 for the potential treatment of CMT1A, spasticity in patients with MS, pain, and overactive bladder.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top